Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.44 |
| ▸ | ADH1A | P07327 | 4/20 | 0.44 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 2/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132984 | 0.75 | ADH1B (0.48) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL21319727 | 0.69 | ADH1B (0.65) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL1781470 | 0.68 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL13189336 | 0.68 | ADH1B (0.52) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL115609 | 0.64 | — | — | |
| SCHEMBL21997344 | 0.64 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL19658308 | 0.64 | ADH1B (1.00) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL19872335 | 0.64 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL360144 | 0.63 | — | — | |
| Hydrochloric Acid SCHEMBL9205102 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | ADH1B 1869/4885ADH1A 1451/4885ADH1C 1626/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | ADH1B 2018/4885ADH1A 1342/4885ADH1C 1312/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | ADH1B 1823/4885ADH1A 1374/4885ADH1C 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.